Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
2014 1
2019 1
2020 4
2021 5
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V, Luo J, Parmar A, Dai WF, Beca JM, Raphael MJ, Isaranuwatchai W, Habbous S, Tadrous M, Earle CC, Biagi JJ, Mittmann N, Arias J, Gavura S, Chan KKW. Arciero V, et al. Among authors: beca jm. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac047. doi: 10.1093/jncics/pkac047. JNCI Cancer Spectr. 2022. PMID: 35758620 Free PMC article.
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, Kendell C, Folkins C, Somayaji C, Dowden J, Cheung W, Strumpf E, Beca JM, McClure C, Urquhart R, McDonald JT, Alvi R, Turner D, Peacock S, Denburg A, Mercer RE, Muñoz C, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Dai WF, et al. Among authors: beca jm. Curr Oncol. 2022 Mar 17;29(3):2046-2063. doi: 10.3390/curroncol29030165. Curr Oncol. 2022. PMID: 35323365 Free PMC article.
Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces.
Beca JM, Dai WF, Pataky RE, Tran D, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Beca JM, et al. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e7-e17. doi: 10.1016/j.clon.2021.08.009. Epub 2021 Aug 26. Clin Oncol (R Coll Radiol). 2022. PMID: 34456106
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
Habbous S, Tai X, Beca JM, Arias J, Raphael MJ, Parmar A, Crespo A, Cheung MC, Eisen A, Eskander A, Singh S, Trudeau M, Gavura S, Dai WF, Irish J, Krzyzanowska M, Lapointe-Shaw L, Naipaul R, Peacock S, Yeung L, Forbes L, Chan KKW. Habbous S, et al. Among authors: beca jm. JAMA Netw Open. 2022 Aug 1;5(8):e2225118. doi: 10.1001/jamanetworkopen.2022.25118. JAMA Netw Open. 2022. PMID: 35917122 Free PMC article.
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Dai WF, Habbous S, Saluja R, Beca JM, Raphael M, Arias J, Gavura S, Earle CC, Biagi JJ, Coburn N, Chan KKW. Dai WF, et al. Among authors: beca jm. Clin Oncol (R Coll Radiol). 2023 May;35(5):e303-e311. doi: 10.1016/j.clon.2023.02.008. Epub 2023 Feb 16. Clin Oncol (R Coll Radiol). 2023. PMID: 36863956
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Dai WF, Craig E, Fraser B, Chambers A, Mai H, Brown MB, Earle CC, Evans WK, Geirnaert M, Taylor M, Trudeau M, Sperber D, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Dai WF, et al. Among authors: beca jm. Curr Oncol. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392. Curr Oncol. 2021. PMID: 34898572 Free PMC article.
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, Lungu E, Mitera G, Potashnik T, Reiman A, Ritcher T, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group. Dai WF, et al. Among authors: beca jm. Curr Oncol. 2021 Oct 16;28(5):4174-4183. doi: 10.3390/curroncol28050354. Curr Oncol. 2021. PMID: 34677272 Free PMC article.
17 results